Spyre Therapeutics Current Debt

SYRE Stock   27.00  0.50  1.82%   
At present, Spyre Therapeutics' Net Debt To EBITDA is projected to slightly decrease based on the last few years of reporting. . Spyre Therapeutics' financial risk is the risk to Spyre Therapeutics stockholders that is caused by an increase in debt.
 
Debt Ratio  
First Reported
2010-12-31
Previous Quarter
0.22
Current Value
0.2
Quarterly Volatility
0.01367111
 
Credit Downgrade
 
Yuan Drop
 
Covid
At present, Spyre Therapeutics' Non Current Liabilities Total is projected to increase significantly based on the last few years of reporting. The current year's Non Current Liabilities Other is expected to grow to about 49.9 M, whereas Total Current Liabilities is forecasted to decline to about 16.7 M.
  
Check out the analysis of Spyre Therapeutics Fundamentals Over Time.
For information on how to trade Spyre Stock refer to our How to Trade Spyre Stock guide.

Spyre Therapeutics Financial Rating

Spyre Therapeutics financial ratings play a critical role in determining how much Spyre Therapeutics have to pay to access credit markets, i.e., the amount of interest on their issued debt. The threshold between investment-grade and speculative-grade ratings has important market implications for Spyre Therapeutics' borrowing costs.
Piotroski F Score
3
FrailView

Spyre Therapeutics Total Assets Over Time

Spyre Therapeutics Assets Financed by Debt

The debt-to-assets ratio shows the degree to which Spyre Therapeutics uses debt to finance its assets. It includes both long-term and short-term borrowings maturing within one year. It also includes both tangible and intangible assets, such as goodwill.

Spyre Therapeutics Debt Ratio

    
  20.0   
It looks as if most of the Spyre Therapeutics' assets are financed through equity. Typically, companies with high debt-to-asset ratios are said to be highly leveraged. The higher the ratio, the greater risk will be associated with the Spyre Therapeutics' operation. In addition, a high debt-to-assets ratio may indicate a low borrowing capacity of Spyre Therapeutics, which in turn will lower the firm's financial flexibility.

Spyre Net Debt

Net Debt

(99.12 Million)

At present, Spyre Therapeutics' Net Debt is projected to decrease significantly based on the last few years of reporting.

Understaning Spyre Therapeutics Use of Financial Leverage

Spyre Therapeutics' financial leverage ratio helps determine the effect of debt on the overall profitability of the company. It measures Spyre Therapeutics' total debt position, including all outstanding debt obligations, and compares it with Spyre Therapeutics' equity. Financial leverage can amplify the potential profits to Spyre Therapeutics' owners, but it also increases the potential losses and risk of financial distress, including bankruptcy, if Spyre Therapeutics is unable to cover its debt costs.
Last ReportedProjected for Next Year
Net Debt-104.3 M-99.1 M
Short and Long Term Debt Total84.6 M88.8 M
Short Term Debt718.8 K483.7 K
Net Debt To EBITDA 0.43  0.74 
Debt To Equity 0.41  0.37 
Interest Debt Per Share 11.03  9.81 
Debt To Assets 0.22  0.20 
Long Term Debt To Capitalization 0.28  0.25 
Total Debt To Capitalization 0.28  0.25 
Debt Equity Ratio 0.41  0.37 
Debt Ratio 0.22  0.20 
Cash Flow To Debt Ratio(1.06)(1.12)
Please read more on our technical analysis page.

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
When determining whether Spyre Therapeutics is a strong investment it is important to analyze Spyre Therapeutics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Spyre Therapeutics' future performance. For an informed investment choice regarding Spyre Stock, refer to the following important reports:
Check out the analysis of Spyre Therapeutics Fundamentals Over Time.
For information on how to trade Spyre Stock refer to our How to Trade Spyre Stock guide.
You can also try the Portfolio Optimization module to compute new portfolio that will generate highest expected return given your specified tolerance for risk.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Spyre Therapeutics. If investors know Spyre will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Spyre Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(37.90)
Return On Assets
(0.39)
Return On Equity
(0.92)
The market value of Spyre Therapeutics is measured differently than its book value, which is the value of Spyre that is recorded on the company's balance sheet. Investors also form their own opinion of Spyre Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Spyre Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Spyre Therapeutics' market value can be influenced by many factors that don't directly affect Spyre Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Spyre Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Spyre Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Spyre Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

What is Financial Leverage?

Financial leverage is the use of borrowed money (debt) to finance the purchase of assets with the expectation that the income or capital gain from the new asset will exceed the cost of borrowing. In most cases, the debt provider will limit how much risk it is ready to take and indicate a limit on the extent of the leverage it will allow. In the case of asset-backed lending, the financial provider uses the assets as collateral until the borrower repays the loan. In the case of a cash flow loan, the general creditworthiness of the company is used to back the loan. The concept of leverage is common in the business world. It is mostly used to boost the returns on equity capital of a company, especially when the business is unable to increase its operating efficiency and returns on total investment. Because earnings on borrowing are higher than the interest payable on debt, the company's total earnings will increase, ultimately boosting stockholders' profits.

Leverage and Capital Costs

The debt to equity ratio plays a role in the working average cost of capital (WACC). The overall interest on debt represents the break-even point that must be obtained to profitability in a given venture. Thus, WACC is essentially the average interest an organization owes on the capital it has borrowed for leverage. Let's say equity represents 60% of borrowed capital, and debt is 40%. This results in a financial leverage calculation of 40/60, or 0.6667. The organization owes 10% on all equity and 5% on all debt. That means that the weighted average cost of capital is (.4)(5) + (.6)(10) - or 8%. For every $10,000 borrowed, this organization will owe $800 in interest. Profit must be higher than 8% on the project to offset the cost of interest and justify this leverage.

Benefits of Financial Leverage

Leverage provides the following benefits for companies:
  • Leverage is an essential tool a company's management can use to make the best financing and investment decisions.
  • It provides a variety of financing sources by which the firm can achieve its target earnings.
  • Leverage is also an essential technique in investing as it helps companies set a threshold for the expansion of business operations. For example, it can be used to recommend restrictions on business expansion once the projected return on additional investment is lower than the cost of debt.
By borrowing funds, the firm incurs a debt that must be paid. But, this debt is paid in small installments over a relatively long period of time. This frees funds for more immediate use in the stock market. For example, suppose a company can afford a new factory but will be left with negligible free cash. In that case, it may be better to finance the factory and spend the cash on hand on inputs, labor, or even hold a significant portion as a reserve against unforeseen circumstances.

The Risk of Financial Leverage

The most obvious and apparent risk of leverage is that if price changes unexpectedly, the leveraged position can lead to severe losses. For example, imagine a hedge fund seeded by $50 worth of investor money. The hedge fund borrows another $50 and buys an asset worth $100, leading to a leverage ratio of 2:1. For the investor, this is neither good nor bad -- until the asset price changes. If the asset price goes up 10 percent, the investor earns $10 on $50 of capital, a net gain of 20 percent, and is very pleased with the increased gains from the leverage. However, if the asset price crashes unexpectedly, say by 30 percent, the investor loses $30 on $50 of capital, suffering a 60 percent loss. In other words, the effect of leverage is to increase the volatility of returns and increase the effects of a price change on the asset to the bottom line while increasing the chance for profit as well.